2nd Quarter - Report

W STRATEGIES, LLC for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

H.R. 436: Health Care Cost Reduction Act of 2012.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 436 (112th)

Health Issues HCR

Promoted life sciences community and communicated economic and health benefits of the industry. Educated staff on advances in diabetes research and discussed opportunities for further briefing with Congressional Diabetes Caucus. H.R. 5651: Food and Drug Administration Reform Act of 2012, S. 3187: Food and Drug Administration Safety and Innovation Act of 2012 -- issues related to reform of the drug and device approval process and legislative initiatives as well as tracking of FDA performance data, and provisions providing incentives for development of new antibiotics (H.R. 2182: GAIN ACT). Educated staff about analysis of data related to the drug and device approval process at FDA.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3187 (112th), H.R. 2182 (112th), H.R. 5651 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.